醫(yī)學(xué)博士，主治醫(yī)師，畢業(yè)于北京協(xié)和醫(yī)學(xué)院北京協(xié)和醫(yī)院，擅長(zhǎng)胃腸腫瘤的臨床診療工作，同時(shí)從事胃腸腫瘤化療耐藥、腫瘤轉(zhuǎn)移等相關(guān)臨床基礎(chǔ)研究。設(shè)計(jì)并實(shí)施回顧性以及前瞻性臨床研究各1項(xiàng)，以第一或共同第一作者發(fā)表論文9篇，其中SCI論文5篇、中文核心期刊論文2篇。主持2項(xiàng)院?；?，參與多項(xiàng)國(guó)家自然科學(xué)基金，多次參與全國(guó)胃癌學(xué)術(shù)會(huì)議、中國(guó)外科周、國(guó)際外科醫(yī)師、胃腸病學(xué)家和腫瘤學(xué)家協(xié)會(huì)（IASGO）年會(huì)、歐洲神經(jīng)內(nèi)分泌腫瘤年會(huì)、韓國(guó)醫(yī)學(xué)腫瘤學(xué)會(huì)年會(huì)等國(guó)內(nèi)國(guó)際會(huì)議進(jìn)行科研成果展示。

發(fā)表論文

1.戴紅梅，等. 基于傾向性評(píng)分匹配的食管胃結(jié)合部腺癌不同綜合治療模式的單中心回顧性研究. 中華外科雜志; 2022; 60(9):846-852.

2.Hongmei Dai, et al. Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer. Journal of Pancreatology; 2021, 4(2): 106-114. 

3.Hongmei Dai#, Hao Chen#, et al. Early detection of cognitive impairment in patients with insulinoma. Endocrine; 2019, 65(3):524-30. 

4.戴紅梅,等. 主動(dòng)脈旁淋巴結(jié)轉(zhuǎn)移對(duì)胰腺癌可切除性影響的研究進(jìn)展.中華外科雜志; 2019, 57(1)：68-71.

5.Hongmei Dai#, Xianze Wang#,, et al. Overexpression of catechol-O-methyltransferase occurs early in the progression of pancreatic cancer. Journal of Pancreatology; 2018, 1(1): 39-44. 

6.Chen Lin#, Hongmei Dai#, et al. The prognostic impact of primary tumor resection in pancreatic neuroendocrine tumors with synchronous multifocal liver metastases. Pancreatology; 2018, 18(5): 608-614.

7.Mei Liang#, Jialin Jiang#, Hongmei Dai#, et al. Robotic enucleation for pediatric insulinoma with MEN1 syndrome: a case report and literature review. BMC surgery; 2018, 18(1): 44. 

8.Hongmei Dai, et al. Surgery in Overweight Patients with Insulinoma: Effects on Weight Loss. Scandinavian Journal of Gastroenterology, 2017, 52(9): 1037-1041.

9.Hongmei Dai, et al. Pancreatic neuroendocrine tumor cancer stem cells: Potential novel therapeutic targets? Translational Cancer Research, 2016, 5(6): 860-870.